视觉分析骨恶性瘤免疫疗法:从2010年到2023年的图书统计分析
Kaiyu Shen1, Liu Yang1, Shuaiyi Ke2
1The Second Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, China.
Medicine
|March 29, 2024
概括
这份图书统计分析揭示了对骨恶性瘤 (BM) 免疫治疗的研究兴趣日益增长. 关键趋势显示了向PD-L1和单臂研究的转变,为未来的临床应用提供了见解.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 图书统计学 图书统计学
背景情况:
- 骨恶性瘤 (BM) 的复发率和死亡率很高.
- 免疫疗法在癌症治疗中越来越重要.
- 对于BM免疫疗法存在有限的文献计量研究.
研究的目的:
- 分析骨恶性瘤 (BM) 免疫治疗的全球趋势和研究热点.
- 提供关于BM免疫疗法的当前状态和未来前景的见解.
- 引导临床医生和研究人员为BM患者选择适当的免疫疗法策略.
主要方法:
- 2010-2023年英语研究的综合文献搜索 在 Web of Science 核心集合.
- 使用了包括VOSviewer,CiteSpace和R Studio在内的参考资料分析工具.
- 检查了出版趋势,领先的机构,作者,期刊和关键词的演变.
主要成果:
- 分析了719篇文章,显示出版的趋势越来越大,特别是在过去5年.
- 中国领先出版物,德克萨斯大学MD安德森癌症中心作为顶级机构.
- 关键词从"抗瘤活性"和"NK细胞"演变为"PD-L1"",开放标签"和"单臂".
结论:
- 了解BM免疫疗法趋势对于患者选择至关重要.
- 本文献分析为BM免疫疗法开发提供了全面的见解.
- 这项研究为在骨恶性瘤患者中应用免疫治疗提供了实际指导.
相关概念视频
Cancer Survival Analysis
345
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
345
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K


